-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
PerkinElmer, Inc. (NYSE:PKI) Receives Average Recommendation of "Hold" From Brokerages
PerkinElmer, Inc. (NYSE:PKI) Receives Average Recommendation of "Hold" From Brokerages
Shares of PerkinElmer, Inc. (NYSE:PKI – Get Rating) have been given a consensus recommendation of "Hold" by the eleven research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $162.50.
A number of analysts have recently weighed in on PKI shares. Bank of America cut PerkinElmer from a "buy" rating to a "neutral" rating and set a $178.00 price target on the stock. in a research report on Tuesday, August 2nd. Barclays lowered their target price on PerkinElmer from $149.00 to $140.00 and set an "underweight" rating on the stock in a research report on Monday, September 12th. Stifel Nicolaus cut PerkinElmer from a "buy" rating to a "hold" rating and lowered their target price for the company from $190.00 to $170.00 in a research report on Thursday, August 18th. Robert W. Baird raised their target price on PerkinElmer from $198.00 to $202.00 and gave the company an "outperform" rating in a research report on Tuesday, August 2nd. Finally, UBS Group started coverage on PerkinElmer in a research report on Wednesday, July 20th. They issued a "buy" rating and a $160.00 target price on the stock.
Get PerkinElmer alerts:PerkinElmer Trading Down 1.4 %
NYSE:PKI opened at $125.95 on Thursday. The company has a quick ratio of 1.42, a current ratio of 2.02 and a debt-to-equity ratio of 0.63. The business's 50 day moving average is $143.28 and its two-hundred day moving average is $150.73. The company has a market cap of $15.90 billion, a PE ratio of 23.59, a P/E/G ratio of 0.36 and a beta of 1.14. PerkinElmer has a 52 week low of $125.52 and a 52 week high of $203.16.
PerkinElmer (NYSE:PKI – Get Rating) last announced its quarterly earnings results on Monday, August 1st. The medical research company reported $2.32 earnings per share for the quarter, topping analysts' consensus estimates of $2.01 by $0.31. The business had revenue of $1.23 billion for the quarter, compared to analysts' expectations of $1.20 billion. PerkinElmer had a return on equity of 16.68% and a net margin of 13.21%. The business's quarterly revenue was up .1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.83 EPS. On average, analysts predict that PerkinElmer will post 7.83 EPS for the current year.PerkinElmer Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, November 11th. Stockholders of record on Friday, October 21st will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.22%. The ex-dividend date is Thursday, October 20th. PerkinElmer's dividend payout ratio (DPR) is presently 5.24%.
Insider Activity
In other news, insider James M. Mock sold 5,025 shares of PerkinElmer stock in a transaction on Friday, June 24th. The stock was sold at an average price of $145.49, for a total transaction of $731,087.25. Following the transaction, the insider now directly owns 27,577 shares in the company, valued at approximately $4,012,177.73. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider James M. Mock sold 5,025 shares of the firm's stock in a transaction on Friday, June 24th. The stock was sold at an average price of $145.49, for a total transaction of $731,087.25. Following the completion of the sale, the insider now directly owns 27,577 shares of the company's stock, valued at approximately $4,012,177.73. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Andrew Okun sold 3,173 shares of the firm's stock in a transaction on Monday, August 1st. The stock was sold at an average price of $165.42, for a total value of $524,877.66. Following the sale, the insider now directly owns 6,391 shares of the company's stock, valued at $1,057,199.22. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,898 shares of company stock worth $2,083,263. 0.52% of the stock is owned by company insiders.
Institutional Investors Weigh In On PerkinElmer
Several large investors have recently modified their holdings of PKI. HighTower Advisors LLC boosted its stake in shares of PerkinElmer by 16.8% during the 4th quarter. HighTower Advisors LLC now owns 6,258 shares of the medical research company's stock worth $1,260,000 after acquiring an additional 900 shares in the last quarter. American International Group Inc. boosted its position in shares of PerkinElmer by 12.8% in the fourth quarter. American International Group Inc. now owns 38,540 shares of the medical research company's stock worth $7,749,000 after buying an additional 4,378 shares during the period. Invesco Ltd. boosted its position in shares of PerkinElmer by 20.3% in the fourth quarter. Invesco Ltd. now owns 1,158,185 shares of the medical research company's stock worth $232,866,000 after buying an additional 195,758 shares during the period. Public Sector Pension Investment Board boosted its position in shares of PerkinElmer by 11.3% in the fourth quarter. Public Sector Pension Investment Board now owns 21,061 shares of the medical research company's stock worth $4,235,000 after buying an additional 2,130 shares during the period. Finally, Siemens Fonds Invest GmbH boosted its position in shares of PerkinElmer by 3.5% in the fourth quarter. Siemens Fonds Invest GmbH now owns 4,150 shares of the medical research company's stock worth $828,000 after buying an additional 140 shares during the period. 77.06% of the stock is owned by institutional investors.
About PerkinElmer
(Get Rating)
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
See Also
- Get a free copy of the StockNews.com research report on PerkinElmer (PKI)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.
据Marketbeat.com报道,PerkinElmer,Inc.(纽约证券交易所代码:PKI-GET Rating)的股票已被目前涵盖该股票的11家研究公司一致建议持有。一名分析师对该股的评级为卖出,五名分析师给出了持有评级,四名分析师对该公司给予了买入评级。在过去一年更新该股覆盖范围的分析师中,1年目标价的平均水平为162.50美元。
一些分析师最近加入了对PKI股票的看法。美国银行将PerkinElmer的评级从“买入”下调至“中性”,并为该股设定了178.00美元的目标价。在8月2日星期二的一份研究报告中。巴克莱在9月12日周一的一份研究报告中将PerkinElmer的目标价从149.00美元下调至140.00美元,并将该股的评级定为“减持”。Stifel Nicolaus在8月18日周四的一份研究报告中将PerkinElmer的评级从“买入”下调至“持有”,并将该公司的目标价从190.00美元下调至170.00美元。8月2日,罗伯特·W·贝尔德在一份研究报告中将PerkinElmer的目标价从198.00美元上调至202.00美元,并给予该公司“跑赢大盘”的评级。最后,瑞银集团在7月20日星期三的一份研究报告中开始对PerkinElmer进行报道。他们对该股的评级为“买入”,目标价为160.00美元。
到达PerkinElmer警报:PerkinElmer股价下跌1.4%
纽约证券交易所:pki周四开盘报125.95美元。该公司的速动比率为1.42,流动比率为2.02,债务权益比率为0.63。该业务的50日移动均线切入位在143.28美元,200日移动均线切入位在150.73美元。该公司市值159亿美元,市盈率23.59倍,市盈率0.36倍,贝塔系数1.14。PerkinElmer的52周低点为125.52美元,52周高点为203.16美元。
PerkinElmer(纽约证券交易所代码:PKI-GET Rating)上一次公布季度收益是在8月1日星期一。这家医疗研究公司公布本季度每股收益为2.32美元,比分析师普遍预期的2.01美元高出0.31美元。该业务当季营收为12.3亿美元,高于分析师预期的12.亿美元。PerkinElmer的股本回报率为16.68%,净利润率为13.21%。该业务的季度收入同比增长了1.1%。去年同期,该公司每股收益为2.83美元。分析师平均预测,PerkinElmer本年度每股收益将达到7.83欧元。PerkinElmer宣布派息
该公司最近还宣布了季度股息,将于11月11日(星期五)支付。10月21日(星期五)登记在册的股东将获得每股0.07美元的股息。这意味着年化股息为0.28美元,股息收益率为0.22%。除息日期为10月20日星期四。PerkinElmer的股息支付率(DPR)目前为5.24%。
内幕活动
其他消息方面,内部人士詹姆斯·M·莫克在6月24日(星期五)的一次交易中出售了5025股PerkinElmer股票。该股以145.49美元的平均价格出售,总成交金额为731,087.25美元。交易完成后,这位内部人士现在直接持有该公司27,577股股票,价值约4,012,177.73美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可以通过美国证券交易委员会网站。在其他新闻方面,内部人士詹姆斯·M·莫克在6月24日星期五的一次交易中出售了5,025股该公司股票。该股以145.49美元的平均价格出售,总成交金额为731,087.25美元。出售完成后,这位内部人士现在直接拥有该公司27,577股股票,价值约4,012,177.73美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接。此外,内部人士安德鲁·奥肯在8月1日星期一的一次交易中出售了3173股该公司的股票。这只股票的平均售价为165.42美元,总价值为524,877.66美元。出售后,这位内部人士现在直接持有该公司6,391股股票,价值1,057,199.22美元。关于这次销售的披露可以找到这里。在过去的90天里,内部人士卖出了13,898股公司股票,价值2,083,263美元。0.52%的股份由公司内部人士持有。
机构投资者对PerkinElmer的看法
几家大型投资者最近调整了他们的PKI持有量。HighTower Advisors LLC在第四季度将其在PerkinElmer的股份增加了16.8%。HighTower Advisors LLC现在拥有这家医学研究公司6,258股股票,价值1,260,000美元,上个季度又购买了900股。美国国际集团(American International Group Inc.)在第四季度将其在PerkinElmer的股票头寸增加了12.8%。美国国际集团目前持有这家医疗研究公司38,540股股票,价值7,749,000美元,在此期间又购买了4,378股。景顺在第四季度将其在PerkinElmer的股票持仓量提高了20.3%。景顺公司目前持有这家医学研究公司1,158,185股股票,价值232,866,000美元,在此期间又购买了195,758股。公共部门养老金投资委员会在第四季度将其在PerkinElmer股票的头寸增加了11.3%。公共部门养老金投资委员会现在拥有21,061股这家医疗研究公司的股票,价值4,235,000美元,在此期间又购买了2,130股。最后,西门子Fond Invest GmbH在第四季度将其在PerkinElmer的股票头寸提高了3.5%。西门子Fond Invest GmbH目前持有这家医学研究公司4150股股票,价值82.8万美元,在此期间又购买了140股。77.06%的股份由机构投资者持有。
关于PerkinElmer
(获取评级)
PerkinElmer,Inc.为全球诊断、生命科学和应用服务市场提供产品、服务和解决方案。它通过两个部门运行:发现和分析解决方案以及诊断。发现与分析解决方案部门提供一整套解决方案,包括试剂、信息学、检测和成像技术,使科学家能够加强生命科学研究市场的研究突破,以及合同研究和实验室服务。
另请参阅
- 免费获取StockNews.com关于PerkinElmer的研究报告(PKI)
- 对塔吉特来说,最糟糕的时期可能已经过去,但这只股票买起来安全吗?
- 这些液态天然气股票准备好上行了吗?
- 内部人士正在买入的两只有趣的股票
- 诺华在避险市场中仍是一只冒险的股票
- 连续60年提高股息的3只防御性股票
接受PerkinElmer Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对PerkinElmer和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧